MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Tuberculosis drug shows promise against latent bacteria

Back to infectious disease news Blogs list Cancer blog  


Subscribe To Infectious Disease News RSS Feed  RSS content feed What is RSS feed?

Tuberculosis drug shows promise against latent bacteria




A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened therapys for this globally prevalent disease.

Despite numerous therapy advances, tuberculosis (TB) remains a serious disease fueled by co-infection of HIV patients, the rise of drug-resistant strains, and the ability of Mycobacterium tuberculosis to become dormant and linger in the lungs. In fact, one third of the world population is infected, asymptomatically, with latent TB and is at risk of developing active TB disease during their life time.



Tuberculosis drug shows promise against latent bacteria
Tuberculosis bacilli

Anil Koul and his colleagues at Johnson & Johnson tested R207910 on dormant M. tuberculosis in three different laboratory models of latency. R207910 targets a protein (ATP synthase) essential for making cellular energy (ATP) in actively replicating TB. The scientists reasoned that even dormant bacteria, which are essentially physiologically "turned off", still need to produce small quantities of ATP to survive. As such, a block in ATP synthesis might be an Achilles heel for killing dormant bacteria.

This reasoning proved to be correct and R207190 was able to kill dormant bacteria by greater than 95% whereas current drugs like isoniazid had no effect. Surprisingly, they observed that R207910 is slightly more effective in killing dormant bacteria as in comparison to actively replicating ones, a unique spin as all known TB drugs are more effective on replicating bugs. Koul and his colleagues hope to validate these results clinically, and note that ATP synthase should be looked at as a drug target for other persistent bacterial infections.


Posted by: Mark    Source




Did you know?
A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened therapys for this globally prevalent disease.

Medicineworld.org: Tuberculosis drug shows promise against latent bacteria

SARS Main| SARS Abroad| SARS and Goverment| SARS Information in different languages| Media about SARS| Physicians resources for SARS| Reference information for SARS| Updates on SARS|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.